Elayne Gordonov, Market Manager - Global Bio Market at Instron, talks to AZoM about physical testing requirements of syringes, Luer connections, and needle-based injection systems in-line with ISO ...
Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...
YORK, Pa., Aug. 30, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced the development of a unique proprietary range of auto-injectors for ...
Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...
Stevanato has added another drug delivery technology to its portfolio, teaming up with Owen Mumford to provide customers with a two-step, single-use auto-injector that automatically adapts to a range ...
In the past two decades, drug delivery has become a major factor in the advancement of the quality of life and a key factor in the business success of pharmaceutical companies. During this time, ...
Severe allergic reactions can be deadly and epinephrine auto-injectors can help save lives. Rice University students came up with EpiWear, a wearable alternative to EpiPen. Bioengineering majors ...
SHL, the world's largest privately owned designer and manufacturer of advanced drug delivery devices, has just opened a new design and assembly center in the United States. Rapidly growing SHL is ...
Millions of people with severe allergies carry EpiPens to reverse life-threatening allergic reactions. But as the prices of these auto-injectors have soared, more than quintupling since 2004, many ...
Dublin, Nov. 10, 2020 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injector Market by Age group, Dosage, by End-user, and Geography - Global Drivers, Restraints, Opportunities, Trends, and Forecast up to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results